Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OBI-1's force no longer with Inspiration and Ipsen as hemophilia asset goes over to Baxter

This article was originally published in Scrip

Executive Summary

With the sale of OBI-1 (recombinant porcine Factor VIII) to Baxter International for potentially more than $700 million and with the disposition of IB1001 (intravenous recombinant Factor IX) on the horizon, Inspiration Biopharmaceuticals has just months left before the hemophilia-focused company winds down operations after filing for Chapter 11 bankruptcy protection at the end of October (, 1 November 2012).

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts